late
discoveri
acycl
nucleosid
analogu
particular
acyclovir
could
inhibit
dna
replic
herp
simplex
viru
hsv
concentr
far
affect
cellular
dna
synthesi
spark
new
era
antivir
chemotherapi
underli
reason
select
acyclovir
specif
convert
activ
metabolit
hsvencod
thymidin
kinas
unexpect
potenti
exploit
viral
enzym
develop
potent
specif
antivir
drug
clearli
demonstr
acyclovir
subsequ
becam
success
treatment
success
acyclovir
provid
encourag
earli
face
new
viral
pathogen
human
immunodefici
viru
hiv
call
identifi
tent
caus
aid
lead
intens
search
inhibitor
retroviru
success
antihiv
agent
discov
earli
period
also
first
licens
clinic
use
azidothymidin
azt
emerg
screen
effort
around
nucleosid
analogu
select
wellcom
laboratori
evalu
nation
cancer
institut
select
inhibitori
activ
azt
viral
enzym
hiv
revers
transcriptas
compar
enzym
involv
dna
synthesi
normal
cell
provid
therapeut
window
use
two
key
advanc
genom
sequenc
structurebas
drug
design
facilit
new
approach
target
viral
enzym
guid
ration
design
effort
elucid
hiv
life
cycl
aid
genom
sequenc
viru
reveal
viral
encod
aspartyl
proteas
crucial
viral
replic
specif
design
proteas
inhibitor
base
transitionst
peptidomimet
principl
replac
peptid
linkag
noncleav
bond
aid
structur
proteas
ultim
led
introduct
hiv
proteas
inhibitor
combin
drug
nucleosid
revers
transcriptas
inhibitor
began
era
highli
activ
antiretrovir
therapi
haart
transform
hiv
infect
death
sentenc
chronic
manag
diseas
success
end
stori
battl
hiv
resist
antihiv
drug
emerg
often
rapidli
combat
new
agent
exist
class
new
class
drug
serendipit
screen
ration
design
develop
twentyfour
antihiv
drug
receiv
regulatori
approv
eleven
target
hiv
revers
transcriptas
ten
target
hiv
proteas
other
target
hiv
cell
entri
hiv
cell
fusion
hiv
integras
supplementari
inform
tabl
avail
onlin
meanwhil
develop
drug
virus
also
progress
consider
mirror
theme
seen
develop
antihiv
drug
exampl
earli
transitionst
mimicri
also
inspir
design
influenza
viru
neuraminidas
also
known
sialidas
inhibitor
current
mainstay
pharmacolog
defenc
influenza
pandem
also
compound
treatment
strategi
develop
hiv
could
consid
paradigm
develop
similar
approach
treatment
viral
infect
particular
hepat
c
viru
hcv
although
hcv
fundament
differ
hiv
sever
class
drug
target
viral
enzym
case
hcv
rna
replicas
hcv
serin
proteas
might
one
day
combin
way
similar
target
hiv
revers
transcriptas
hiv
aspartyl
proteas
importantli
hcv
combin
antivir
drug
immunomodulatori
interferon
may
erad
infect
someth
still
seem
distant
goal
hiv
therapi
although
hiv
hcv
current
major
focu
antivir
drug
research
detract
import
develop
implement
drug
therapi
sever
viru
infect
includ
hepat
b
viru
influenza
viru
sever
acut
respiratori
syndrom
sar
viru
respiratori
viru
infect
may
emerg
time
haemorrhag
fever
viru
ebola
enceph
viru
west
nile
infect
also
merit
seriou
attent
ongo
need
combat
exist
emerg
viral
infect
call
continu
collabor
medicin
chemist
biomed
research
identifi
develop
new
therapi
har
serendipit
screen
strategi
ration
design
exemplifi
discoveri
acyclovir
hiv
proteas
inhibitor
final
global
health
perspect
continu
effort
make
therapi
avail
need
highli
warrant
